Discovery of cell-permeable inhibitors for human succinyl-CoA:glutarate-CoA transferase

Glutaric Aciduria Type I (GA-1) is a recessive, serious neurometabolic disorder characterized by a build-up of toxic metabolites in the lysine metabolic pathway with no current pharmacological treatment. Previous mouse studies have shown that a deficiency in SUGCT attenuates the accumulation of some of these metabolites in vivo. These results highlight the potential for SUGCT as a therapeutic target in treating GA-1. We had previously identified biochemical inhibitors for SUGCT and had solved the crystal structure of the protein, both apo and bound to an inhibitor. However, we were unable to demonstrate cellular activity for these compounds. In this study, we report findings from additional in vitro high-throughput screening and address these challenges by developing an improved cell-based assay to detect SUGCT inhibition. We show that by improving the permeability of valsartan using its ethyl ester prodrug, SUGCT is effectively inhibited in GA-1 cells. We also identify meclofenamic acid as a new SUGCT inhibitor with cellular activity, providing additional validation and highlighting this enzyme target potential for GA-1.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-16
DOI
https://doi.org/10.64898/2026.11.12.765678
Primary Topic
Metabolism and Genetic Disorders
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Discovery of cell-permeable inhibitors for human succinyl-CoA:glutarate-CoA transferase

Robert J. DeVita, Sander M. Houten, Michael B. Lazarus, Tetyana Dodatko et al.
1 links
bioRxiv (Cold Spring Harbor Laboratory)
Metabolism and Genetic Disorders
preprint

Discovery of cell-permeable inhibitors for human succinyl-CoA:glutarate-CoA transferase

Robert J. DeVita, Sander M. Houten, Michael B. Lazarus, Tetyana Dodatko, Kunal Kumar, Brandon Stauffer, Frank H Rizzo, Chunli Yu
preprint en

Abstract

Glutaric Aciduria Type I (GA-1) is a recessive, serious neurometabolic disorder characterized by a build-up of toxic metabolites in the lysine metabolic pathway with no current pharmacological treatment. Previous mouse studies have shown that a deficiency in SUGCT attenuates the accumulation of some of these metabolites in vivo. These results highlight the potential for SUGCT as a therapeutic target in treating GA-1. We had previously identified biochemical inhibitors for SUGCT and had solved the crystal structure of the protein, both apo and bound to an inhibitor. However, we were unable to demonstrate cellular activity for these compounds. In this study, we report findings from additional in vitro high-throughput screening and address these challenges by developing an improved cell-based assay to detect SUGCT inhibition. We show that by improving the permeability of valsartan using its ethyl ester prodrug, SUGCT is effectively inhibited in GA-1 cells. We also identify meclofenamic acid as a new SUGCT inhibitor with cellular activity, providing additional validation and highlighting this enzyme target potential for GA-1.

bioRxiv (Cold Spring Harbor Laboratory)
Icahn School of Medicine at Mount Sinai (US)
National Institutes of Health, National Institute of General Medical Sciences
Good health and well-being
Metabolism and Genetic Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon